Login to Your Account

Oryzon shares beat back after Roche returns rights to ORY-1001

By Marie Powers
News Editor

Thursday, July 20, 2017

Oryzon Genomics SA is losing its only partner, for lead candidate ORY-1001 (RG-6016), after Roche Holding AG reprioritized its pipeline and abandoned development of the lysine specific demethylase-1 (LSD1) inhibitor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription